Request Demo
Last update 16 May 2026
SCTB39-1
Last update 16 May 2026
Overview
Basic Info
Drug Type Trispecific antibody |
Synonyms SCTB39-1 |
Target |
Action inhibitors |
Mechanism CTLA4 inhibitors(Cytotoxic T-Lymphocyte-Associated Antigen 4 inhibitors), PDL1 inhibitors(Programmed death-ligand 1 inhibitors), TIGIT inhibitors(T cell immunoglobulin and ITIM domains inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
2
Clinical Trials associated with SCTB39-1NCT07050641
An Open Multi-center Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of SCTB39-1 in Adult Patients With Advanced Malignant Solid Tumours
CTR20261827
一项评估SCTB41和SCTB39-1联合或不联合标准治疗在晚期恶性实体瘤患者中的安全耐受性、药代动力学和抗肿瘤活性的开放、多中心的Ib/II期临床试验
[Translation] An open-label, multicenter phase Ib/II clinical trial evaluating the safety, tolerability, pharmacokinetics, and antitumor activity of SCTB41 and SCTB39-1, in combination with or without standard therapy, in patients with advanced malignant solid tumors.
100 Clinical Results associated with SCTB39-1
Login to view more data
100 Translational Medicine associated with SCTB39-1
Login to view more data
100 Patents (Medical) associated with SCTB39-1
Login to view more data
100 Deals associated with SCTB39-1
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Advanced Malignant Solid Neoplasm | Phase 2 | China | 23 Jun 2025 | |
| Advanced Malignant Solid Neoplasm | Phase 2 | China | 23 Jun 2025 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free